BioSpace News Archive

Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.

Savara Inc. today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2 trial.

Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism.

TFF Pharmaceuticals, Inc. announced that the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded the Company a Direct to Phase II Small Business Innovation Research grant of approximately $2.97 million to continue development of a novel, pan-flu multivariant mucosal vaccine using the Company’s Thin Film Freezing technology.

Inteleos, a nonprofit global healthcare certification organization, is partnering with Sonography Canada, the national credentialing body and professional association for sonographers in Canada, to offer Canadian sonographers an opportunity to earn specific US credentials through the American Registry for Diagnostic Medical Sonography.

Anthos Therapeutics presented new data in collaboration with two internationally recognized patient advocacy groups, detailing the impacts of patient-relevant bleeding on individuals prescribed anticoagulants.

Tonix Pharmaceuticals Holding Corp. today announced that they have entered into an agreement to acquire two currently-marketed products from Upsher-Smith Laboratories, LLC (Upsher-Smith): Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults.

Chemomab Therapeutics Ltd. today reported that it presented two scientific posters supporting the clinical rationale for the company’s primary sclerosing cholangitis (PSC) program at EASL 2023, the Annual Congress of the European Association for the Study of the Liver, which took place June 21-24, 2023 in Vienna, Austria.

Actinium Pharmaceuticals, Inc. today announced that the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting selected Abstract 685 titled “Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia.

Eupraxia Pharmaceuticals Inc. today announced positive results from its Phase 2b clinical trial of EP-104IAR for pain associated with knee osteoarthritis (“OA”). EP-104IAR met its primary endpoint with a clinically meaningful and statistically significant (p=0.004) improvement over vehicle-placebo in WOMAC Pain at 12 weeks.